LMR Partners’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $21.3M | Buy |
116,131
+107,501
| +1,246% | +$19.8M | 0.05% | 202 |
|
|
2025
Q4 | $1.52M | Buy |
+8,630
| New | +$1.41M | ﹤0.01% | 882 |
|
|
2025
Q2 | – | Sell |
-15,802
| Closed | -$2.16M | – | 1390 |
|
|
2025
Q1 | $2.16M | Buy |
15,802
+1,302
| +9% | +$186K | 0.02% | 657 |
|
|
2024
Q4 | $2.22M | Buy |
14,500
+6,379
| +79% | +$1.08M | 0.02% | 573 |
|
|
2024
Q3 | $1.57M | Buy |
8,121
+1,661
| +26% | +$347K | 0.01% | 659 |
|
|
2024
Q2 | $1.5M | Buy |
+6,460
| New | +$1.4M | 0.01% | 603 |
|
|
2023
Q4 | – | Sell |
-15,294
| Closed | -$3.93M | – | 1002 |
|
|
2023
Q3 | $3.93M | Sell |
15,294
-160,027
| -91% | -$42.8M | 0.04% | 288 |
|
|
2023
Q2 | $49.9M | Buy |
175,321
+139,878
| +395% | +$41.6M | 0.55% | 37 |
|
|
2023
Q1 | $9.85M | Buy |
+35,443
| New | +$9.81M | 0.15% | 162 |
|
|
2022
Q1 | – | Sell |
-23,381
| Closed | -$5.61M | – | 1227 |
|
|
2021
Q4 | $5.61M | Buy |
23,381
+3,185
| +16% | +$819K | 0.06% | 245 |
|
|
2021
Q3 | $5.71M | Sell |
20,196
-2,610
| -11% | -$855K | 0.06% | 231 |
|
|
2021
Q2 | $7.9M | Buy |
22,806
+9,715
| +74% | +$2.94M | 0.12% | 156 |
|
|
2021
Q1 | $3.66M | Sell |
13,091
-54,630
| -81% | -$14.7M | 0.09% | 206 |
|
|
2020
Q4 | $16.6M | Buy |
+67,721
| New | +$17.5M | 0.26% | 46 |
|
|
2020
Q1 | – | Sell |
-52,401
| Closed | -$15.5K | – | 268 |
|
|
2019
Q4 | $15.5K | Buy |
+52,401
| New | +$14.5M | 0.03% | 56 |
|
|
2018
Q2 | – | Sell |
-3,991
| Closed | -$1.27M | – | 481 |
|
|
2018
Q1 | $1.27M | Hold |
3,991
| – | – | 0.13% | 149 |
|
|
2017
Q4 | $1.27M | Buy |
+3,991
| New | +$1.28M | 0.13% | 149 |
|
|
2017
Q3 | – | Sell |
-6,099
| Closed | -$1.66M | – | 341 |
|
|
2017
Q2 | $1.66M | Sell |
6,099
-2,188
| -26% | -$579K | 0.1% | 203 |
|
|
2017
Q1 | $2.27M | Buy |
8,287
+4,871
| +143% | +$1.38M | 0.22% | 75 |
|
|
2016
Q4 | $969K | Buy |
+3,416
| New | +$1.01M | 0.15% | 153 |
|
|
2015
Q3 | – | Sell |
-5,819
| Closed | -$2.35M | – | 325 |
|
|
2015
Q2 | $2.35M | Buy |
5,819
+4,317
| +287% | +$1.73M | 0.29% | 84 |
|
|
2015
Q1 | $634K | Sell |
1,502
-86
| -5% | -$33.9K | 0.09% | 252 |
|
|
2014
Q4 | $539K | Buy |
+1,588
| New | +$514K | 0.07% | 279 |
|
|
2014
Q3 | – | Sell |
-10,195
| Closed | -$3.21M | – | 340 |
|
|
2014
Q2 | $3.21M | Buy |
+10,195
| New | +$3.07M | 0.27% | 100 |
|
Other funds holding BIIB
VCM
VPM
LMR Partners's BIIB Position: Q1 2026 in Review
LMR Partners increased its Biogen (BIIB) stake by 1,246% in Q1 2026, buying an estimated $19.8M and bringing the position to 116,131 shares worth $21.3M. The position accounts for 0.05% of the portfolio, ranked #202.
LMR Partners first reported a position in BIIB in Q2 2014 and has held it in 24 quarters since. The position peaked at $49.9M in Q2 2023. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- LMR Partners held 116,131 shares of Biogen worth $21.3M as of Q1 2026.
- LMR Partners bought 107,501 Biogen shares in Q1 2026, an estimated $19.8M.
- Biogen made up 0.05% of LMR Partners's portfolio in Q1 2026, its #202 holding.
- LMR Partners first reported a position in Biogen in Q2 2014 and has held it in 24 quarters since.
- LMR Partners's Biogen position peaked at $49.9M in Q2 2023.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.